evonetix Stock
evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA.
Sign up today and learn more about evonetix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About evonetix Stock
We are a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
Funding History
January 2018 | $12.3M |
---|---|
July 2018 | $1.3M |
Management
Chief Technology Officer
Matthew Hayes
Director
Ray Edgson
Chief Scientific Officer
Joseph Brennan
CEO
Tim Brears
Press
businessweekly - Apr, 8 2024
Back to the future as Diston takes CEO role in Evonetix rebuildfinance - Mar, 1 2024
Evonetix Announces Agreement for Revolutionary Gene Synthesis Platform with Analog Devicesaltafrica - Feb, 26 2024
Persistent invests in EcoNetixbusinessweekly - Feb, 19 2024
Evonetix and Analog Devices Inc to progress revolutionary gene synthesis platformbusinessweekly - Jan, 28 2024
Record entry and a shortlist oozing quality for Business ...